RON is not a prognostic marker for resectable pancreatic cancer

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Tactacan, Carole M ^a   Chang, David K ^a,b,c   Cowley, Mark J ^a   Humphrey, Emily S ^a   Wu, Jianmin ^a   Gill, Anthony J ^a,d,e   Chou, Angela ^a,f   Nones, Katia ^a,g   Grimmond, Sean M ^a,g   Sutherland, Robert L ^a   Biankin, Andrew V ^a,b,c   Daly, Roger J ^a  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f ST VINCENT S HOSPITAL   (Australia)

^g UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Biomarker; Chemotherapy; Gemcitabine; Receptor tyrosine kinase

Indexed keywords

PROTEIN TYROSINE KINASE; RECEPTOR TYROSINE KINASE RON; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CELL INVASION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PANCREAS CANCER; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SEX; TUMOR LOCALIZATION; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR PROTEIN-TYROSINE KINASES; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84865828068     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-395     Document Type: Article

References (27)

1. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001, 358(9293):1576-1585. 10.1016/S0140-6736(01)06651-X, 11716884.
2. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004, 350(12):1200-1210. 10.1056/NEJMoa032295, 15028824.
3. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg 1997, 21(2):195-200. 10.1007/s002689900215, 8995078.
4. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007, 297(3):267-277. 10.1001/jama.297.3.267, 17227978.
5. Samuel N, Hudson TJ. The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma. Nat Rev Gastroenterol Hepatol 2012, 9(2):77-87.
6. van de Vijver MJ, He YD, Van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347(25):1999-2009. 10.1056/NEJMoa021967, 12490681.
7. Jamieson NB, Carter CR, McKay CJ, Oien KA. Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Clin Cancer Res 2011, 17(10):3316-3331. 10.1158/1078-0432.CCR-10-3284, 21444679.
8. Biankin AV, Kench JG, Colvin EK, Segara D, Scarlett CJ, Nguyen NQ, Chang DK, Morey AL, Lee CS, Pinese M, et al. Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. Gastroenterology 2009, 137(2):558-568. 568 e551-511, 10.1053/j.gastro.2009.04.009, 19376121.
9. Wagh PK, Peace BE, Waltz SE. Met-related receptor tyrosine kinase Ron in tumor growth and metastasis. Adv Cancer Res 2008, 100:1-33.
10. Camp ER, Yang A, Gray MJ, Fan F, Hamilton SR, Evans DB, Hooper AT, Pereira DS, Hicklin DJ, Ellis LM. Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target. Cancer 2007, 109(6):1030-1039. 10.1002/cncr.22490, 17311308.
11. Logan-Collins J, Thomas RM, Yu P, Jaquish D, Mose E, French R, Stuart W, McClaine R, Aronow B, Hoffman RM, et al. Silencing of RON receptor signaling promotes apoptosis and gemcitabine sensitivity in pancreatic cancers. Cancer Res 2010, 70(3):1130-1140. 10.1158/0008-5472.CAN-09-0761, 2943733, 20103639.
12. Thomas RM, Toney K, Fenoglio-Preiser C, Revelo-Penafiel MP, Hingorani SR, Tuveson DA, Waltz SE, Lowy AM. The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Res 2007, 67(13):6075-6082. 10.1158/0008-5472.CAN-06-4128, 17616662.
13. Catenacci DV, Cervantes G, Yala S, Nelson EA, El-Hashani E, Kanteti R, El Dinali M, Hasina R, Bragelmann J, Seiwert T, et al. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther 2011, 12(1):9-46. 10.4161/cbt.12.1.15747, 3149873, 21543897.
14. Welm AL, Sneddon JB, Taylor C, Nuyten DS, van de Vijver MJ, Hasegawa BH, Bishop JM. The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proc Natl Acad Sci U S A 2007, 104(18):7570-7575. 10.1073/pnas.0702095104, 1855278, 17456594.
15. Liu X, Zhao L, Derose YS, Lin YC, Bieniasz M, Eyob H, Buys SS, Neumayer L, Welm AL. Short-form ron promotes spontaneous breast cancer metastasis through Interaction with Phosphoinositide 3-Kinase. Genes Cancer 2011, 2(7):753-762. 10.1177/1947601911421924, 3218405, 22207901.
16. Australian Pancreatic Cancer Network [www.pancreaticcancer.net.au].
17. International Cancer Genome Consortium [www.icgc.org].
18. Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabe RR, Bhan MK, Calvo F, Eerola I, Gerhard DS, et al. International network of cancer genome projects. Nature 2010, 464(7291):993-998. 10.1038/nature08987, 2902243, 20393554.
19. Du P, Kibbe WA, Lin SM. lumi: a pipeline for processing Illumina microarray. Bioinformatics 2008, 24(13):1547-1548. 10.1093/bioinformatics/btn224, 18467348.
20. Kent WJ. BLAT-the BLAST-like alignment tool. Genome Res 2002, 12(4):656-664. 187518, 11932250.
21. Barbosa-Morais NL, Dunning MJ, Samarajiwa SA, Darot JF, Ritchie ME, Lynch AG, Tavare S. A re-annotation pipeline for Illumina BeadArrays: improving the interpretation of gene expression data. Nucleic Acids Res 2010, 38(3):e17. 10.1093/nar/gkp942, 2817484, 19923232.
22. Strimpakos A, Saif MW, Syrigos KN. Pancreatic cancer: from molecular pathogenesis to targeted therapy. Cancer Metastasis Rev 2008, 27(3):495-522. 10.1007/s10555-008-9134-y, 18427734.
23. O'Reilly EM, Abou-Alfa GK. Cytotoxic therapy for advanced pancreatic adenocarcinoma. Semin Oncol 2007, 34(4):347-353. 10.1053/j.seminoncol.2007.05.009, 17674963.
24. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25(15):1960-1966. 10.1200/JCO.2006.07.9525, 17452677.
25. Ueda S, Ogata S, Tsuda H, Kawarabayashi N, Kimura M, Sugiura Y, Tamai S, Matsubara O, Hatsuse K, Mochizuki H. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 2004, 29(1):e1-8. 10.1097/00006676-200407000-00061, 15211117.
26. O'Toole JM, Rabenau KE, Burns K, Lu D, Mangalampalli V, Balderes P, Covino N, Bassi R, Prewett M, Gottfredsen KJ, et al. Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member. Cancer Res 2006, 66(18):9162-9170. 10.1158/0008-5472.CAN-06-0283, 16982759.
27. Zhang Y, Kaplan-Lefko PJ, Rex K, Yang Y, Moriguchi J, Osgood T, Mattson B, Coxon A, Reese M, Kim TS, et al. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo. Cancer Res 2008, 68(16):6680-6687. 10.1158/0008-5472.CAN-07-6782, 18701492.